NEW YORK, Jan. 31, 2017 -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in United States District Court for the Southern District of New York on behalf of all persons or entities that purchased BT Group plc ("BT Group" or the "Company") (NYSE:BT) American Depositary Receipts (“ADRs”) between May 23, 2013, and January 23, 2017, inclusive ("Class Period").
Investors who have incurred losses in BT Group plc ADRs are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may request the filed complaint and obtain additional information concerning the action on our website, www.whafh.com.
If you purchased ADRs of BT Group plc within the class period and would like to become involved in assisting the litigation process, you may, no later than March 27, 2017, request that the Court appoint you lead plaintiff of the proposed class.
The filed complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that (i) BT Group's Italian division had engaged in improper accounting practices; (ii) as a result, BT Group significantly overstated its earnings; (iii) the foregoing facts, when they became known, would foreseeably cause BT Group to cut its revenue, earnings, and free cash flow forecasts; and (iv) as a result, BT Group's public statements were materially false and misleading.
Specifically, on October 27, 2016, the Company announced that it uncovered "inappropriate management behavior" at its Italian division. BT Group revealed to investors that it "conducted an initial internal investigation" which included reviewing accounting practices during which the Company "identified certain historical accounting errors and reassessed certain areas of management judgment." As a result, the Company announced that it had "written down the value of items on the balance sheet by £145 [million]."
On this news, BT Group's ADRs fell from $23.82 on October 26, 2016 to a closing price of $23.25 on October 27, 2016 —a $0.57 or a 2.39% drop.
On January 24, 2017, BT Group issued a news release entitled “Update on investigation into BT’s Italian business and on BT Group outlook.” On this news, BT Group’s ADR price fell $5.05, or 20.67%, to close at $19.38 on January 24, 2017.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein Adler Freeman & Herz LLP by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.
## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
Contact: Wolf Haldenstein Adler Freeman & Herz LLP Kevin Cooper, Esq. Gregory Stone, Director of Case and Financial Analysis Email: [email protected], [email protected] or [email protected] Tel: (800) 575-0735 or (212) 545-4774


Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Anta Sports Expands Global Footprint With Strategic Puma Stake
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Washington Post Publisher Will Lewis Steps Down After Layoffs
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Samsung Electronics Shares Jump on HBM4 Mass Production Report 



